Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2001 1
2002 2
2003 1
2004 2
2005 4
2006 1
2008 3
2009 4
2010 2
2011 5
2012 2
2013 7
2014 6
2015 4
2016 2
2017 2
2018 5
2019 3
2020 17
2021 23
2022 17
2023 17
2024 6
2025 12
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Jonmarker S, Hollenberg J, Dahlberg M, Stackelberg O, Litorell J, Everhov ÅH, Järnbert-Pettersson H, Söderberg M, Grip J, Schandl A, Günther M, Cronhjort M. Jonmarker S, et al. Crit Care. 2020 Nov 23;24(1):653. doi: 10.1186/s13054-020-03375-7. Crit Care. 2020. PMID: 33225952 Free PMC article.
BACKGROUND: A substantial proportion of critically ill COVID-19 patients develop thromboembolic complications, but it is unclear whether higher doses of thromboprophylaxis are associated with lower mortality rates. ...Thromboprophylaxis dosage w …
BACKGROUND: A substantial proportion of critically ill COVID-19 patients develop thromboembolic complications, but it is uncle …
Thromboprophylaxis in Hospitalized Non-Critically Ill Patients With Mild-to-Moderate COVID-19 Infection: A Systematic Review and Meta-Analysis.
Hafiz A, Alkofide H, Al Sulaiman K, Joharji H, Aljohani S, Sarkhi KA, Alharbi R, Korayem GB, AlFaifi M, Alsohimi S, Aljuhani O. Hafiz A, et al. Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231191123. doi: 10.1177/10760296231191123. Clin Appl Thromb Hemost. 2023. PMID: 37547931 Free PMC article.
The evidence that supports the preferred thromboprophylaxis regimen in non-critically ill patients with mild to moderate COVID-19 is still limited. ...In medically ill patients with COVID-19, there is no difference between standard and intermediate to …
The evidence that supports the preferred thromboprophylaxis regimen in non-critically ill patients with mild to moderat …
Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials.
Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Alhazzani W, et al. Crit Care Med. 2013 Sep;41(9):2088-98. doi: 10.1097/CCM.0b013e31828cf104. Crit Care Med. 2013. PMID: 23782973
OBJECTIVE: Venous thromboembolism prevention during critical illness is a widely used quality metric. The objective of this systematic review was to systematically review the efficacy and safety of heparin thromboprophylaxis in medical-surgical patients in th …
OBJECTIVE: Venous thromboembolism prevention during critical illness is a widely used quality metric. The objective of this sy …
Thromboprophylaxis and Risk Factors for Venous Thromboembolism in Critically Ill Children: A Hospital-Based Case-Control Study.
Ijioma CE, Uzor NO, Jolaoye OO, Ndukwe U, Nwokeafor IL, Okafor CC, Ben JE, Akabueze E, Ngumoha WO. Ijioma CE, et al. Cureus. 2025 Aug 31;17(8):e91324. doi: 10.7759/cureus.91324. eCollection 2025 Aug. Cureus. 2025. PMID: 41035602 Free PMC article.
This study aimed to evaluate the use, effectiveness, and clinical outcomes of thromboprophylaxis in critically ill pediatric patients and to identify independent predictors of thromboembolic events. ...Conclusions Thromboprophylaxis, particularly pharm …
This study aimed to evaluate the use, effectiveness, and clinical outcomes of thromboprophylaxis in critically ill pedi …
Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach.
Sahle BW, Pilcher D, Peter K, McFadyen JD, Litton E, Bucknall T. Sahle BW, et al. Thromb J. 2023 May 23;21(1):59. doi: 10.1186/s12959-023-00499-y. Thromb J. 2023. PMID: 37221578 Free PMC article.
BACKGROUND: Venous thromboembolism (VTE) prophylaxis is effective in reducing VTE events, however, its impact on mortality is unclear. We examined the association between omission of VTE prophylaxis within the first 24 h after intensive care unit (ICU) admission and hospit …
BACKGROUND: Venous thromboembolism (VTE) prophylaxis is effective in reducing VTE events, however, its impact on mortality is unclear …
Thrombo-prophylaxis in acutely ill medical and critically ill patients.
Saigal S, Sharma JP, Joshi R, Singh DK. Saigal S, et al. Indian J Crit Care Med. 2014 Jun;18(6):382-91. doi: 10.4103/0972-5229.133902. Indian J Crit Care Med. 2014. PMID: 24987238 Free PMC article. Review.
Thrombo-prophylaxis has been shown to reduce the incidence of pulmonary embolism (PE) and mortality in surgical patients. The purpose of this review is to find out the evidence-based clinical practice criteria of deep vein thrombosis (DVT) prophylaxis in acutely ill …
Thrombo-prophylaxis has been shown to reduce the incidence of pulmonary embolism (PE) and mortality in surgical patients. The purpose …
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Turgeon AF, Kornblith LZ, Kahn SR, Marshall JC, Kim KS, Houston BL, Derde LPG, Cushman M, Tritschler T, Angus DC, Godoy LC, McQuilten Z, Kirwan BA, Farkouh ME, Brooks MM, Lewis RJ, Berry LR, Lorenzi E, Gordon AC, Ahuja T, Al-Beidh F, Annane D, Arabi YM, Aryal D, Baumann Kreuziger L, Beane A, Bhimani Z, Bihari S, Billett HH, Bond L, Bonten M, Brunkhorst F, Buxton M, Buzgau A, Castellucci LA, Chekuri S, Chen JT, Cheng AC, Chkhikvadze T, Coiffard B, Contreras A, Costantini TW, de Brouwer S, Detry MA, Duggal A, Džavík V, Effron MB, Eng HF, Escobedo J, Estcourt LJ, Everett BM, Fergusson DA, Fitzgerald M, Fowler RA, Froess JD, Fu Z, Galanaud JP, Galen BT, Gandotra S, Girard TD, Goodman AL, Goossens H, Green C, Greenstein YY, Gross PL, Haniffa R, Hegde SM, Hendrickson CM, Higgins AM, Hindenburg AA, Hope AA, Horowitz JM, Horvat CM, Huang DT, Hudock K, Hunt BJ, Husain M, Hyzy RC, Jacobson JR, Jayakumar D, Keller NM, Khan A, Kim Y, Kindzelski A, King AJ, Knudson MM, Kornblith AE, Kutcher ME, Laffan MA, Lamontagne F, Le G… See abstract for full author list ➔ REMAP-CAP Investigators, et al. N Engl J Med. 2021 Aug 26;385(9):777-789. doi: 10.1056/NEJMoa2103417. Epub 2021 Aug 4. N Engl J Med. 2021. PMID: 34351722 Free PMC article. Clinical Trial.
BACKGROUND: Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19. M …
BACKGROUND: Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid …
Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
REMAP-CAP Writing Committee for the REMAP-CAP Investigators; Bradbury CA, Lawler PR, Stanworth SJ, McVerry BJ, McQuilten Z, Higgins AM, Mouncey PR, Al-Beidh F, Rowan KM, Berry LR, Lorenzi E, Zarychanski R, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Bhimani Z, Bihari S, Bonten MJM, Brunkhorst FM, Buzgau A, Buxton M, Carrier M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Fitzgerald M, Girard TD, Goligher EC, Goossens H, Haniffa R, Hills T, Huang DT, Horvat CM, Hunt BJ, Ichihara N, Lamontagne F, Leavis HL, Linstrum KM, Litton E, Marshall JC, McAuley DF, McGlothlin A, McGuinness SP, Middeldorp S, Montgomery SK, Morpeth SC, Murthy S, Neal MD, Nichol AD, Parke RL, Parker JC, Reyes LF, Saito H, Santos MS, Saunders CT, Serpa-Neto A, Seymour CW, Shankar-Hari M, Singh V, Tolppa T, Turgeon AF, Turner AM, van de Veerdonk FL, Green C, Lewis RJ, Angus DC, McArthur CJ, Berry S, Derde LPG, Webb SA, Gordon AC. REMAP-CAP Writing Committee for the REMAP-CAP Investigators, et al. JAMA. 2022 Apr 5;327(13):1247-1259. doi: 10.1001/jama.2022.2910. JAMA. 2022. PMID: 35315874 Free PMC article. Clinical Trial.
IMPORTANCE: The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain. OBJECTIVE: To determine whether antiplatelet therapy improves outcomes for critically ill adults with COVID-19. ...Enrollment was discontinued after …
IMPORTANCE: The efficacy of antiplatelet therapy in critically ill patients with COVID-19 is uncertain. OBJECTIVE: To determin …
Omission of early thromboprophylaxis and mortality in critically ill patients: a multicenter registry study.
Ho KM, Chavan S, Pilcher D. Ho KM, et al. Chest. 2011 Dec;140(6):1436-46. doi: 10.1378/chest.11-1444. Epub 2011 Sep 22. Chest. 2011. PMID: 21940768
This study aimed to assess the association between omission of early thromboprophylaxis for > 24 h after ICU admission and mortality in critically ill patients. METHODS: This study involved 175,665 critically ill adult patients admitte …
This study aimed to assess the association between omission of early thromboprophylaxis for > 24 h after ICU admission and mort …
Sex differences in thromboprophylaxis of the critically ill: a secondary analysis of a randomized trial.
Burns KEA, Heels-Ansdell D, Thabane L, Kahn SR, Lauzier F, Mehta S, Ostermann M, Bhuptani P, Crowther MA, Finfer S, Cook DJ; PROTECT Investigators, the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Burns KEA, et al. Can J Anaesth. 2023 Jun;70(6):1008-1018. doi: 10.1007/s12630-023-02457-8. Epub 2023 Jun 13. Can J Anaesth. 2023. PMID: 37310606 Clinical Trial. English.
PURPOSE: Venous thromboembolism (VTE) is a common complication of critical illness. Sex- or gender-based analyses are rarely conducted and their effect on outcomes is unknown. ...We did not identify a significant effect modification by sex on mortality. CONCL …
PURPOSE: Venous thromboembolism (VTE) is a common complication of critical illness. Sex- or gender-based analyses are rarely c …
139 results